Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020. [More]
ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

ASTRO appreciates Supreme Court's decision to uphold consumer tax credits under the ACA

The American Society for Radiation Oncology appreciates yesterday's ruling by the United States Supreme Court affirming the Affordable Care Act in its decision on King v. Burwell. [More]
Lamont R Jones receives 2015 Research Scholar Award to study pathogenesis of keloids

Lamont R Jones receives 2015 Research Scholar Award to study pathogenesis of keloids

Lamont R Jones, M.D., vice chair of the Department of Otolaryngology-Head & Neck Surgery at Henry Ford Hospital, received the 2015 Research Scholar Award from the Educational and Research Foundation for the American Academy of Facial Plastic and Reconstructive Surgery to continue his efforts to study the pathogenesis of keloids and improve understanding of how keloid scars develop. [More]
Researchers highlight important factors that impact early-stage breast cancer patients' access to BCT

Researchers highlight important factors that impact early-stage breast cancer patients' access to BCT

The first comprehensive national review of breast-conserving therapy (BCT) shows that over the last 13 years rates of this treatment modality for early-stage breast cancer have increased at a steady pace. However, the review also highlights important demographic factors that impact which patients have access to BCT. [More]
Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Elekta's Esteya electronic brachytherapy improves outcomes in patients with basal cell carcinoma

Physicians at La Fe University and Polytechnic Hospital - Valencia presented their early clinical outcome data on the use of Esteya electronic brachytherapy for the treatment of basal cell carcinoma in a paper in the current issue of Journal of Contemporary Brachytherapy. The ongoing study showed 100 percent complete response and excellent cosmetic outcome in all lesions treated to date with Esteya. [More]
Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Breakthrough discovery on element transformation could lead to new way for treating cancer with radiation

Chemists at Tufts University's School of Arts and Sciences, collaborating with PerkinElmer and UCL (University College London), have witnessed atoms of one chemical element morph into another for the first time ever -- a feat that produced an unexpected outcome that could lead to a new way to safely treat cancer with radiation. [More]
Lawson researchers find radiation-resistant stem cell population in the colon linked to cancer growth

Lawson researchers find radiation-resistant stem cell population in the colon linked to cancer growth

Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer. [More]
Stage IIIB NSCLC patients may benefit from surgical resection in combination with chemo or radiation therapy

Stage IIIB NSCLC patients may benefit from surgical resection in combination with chemo or radiation therapy

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery. [More]
Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Elekta has signed a contract with one of Korea's most advanced hospitals, Samsung Medical Center in Seoul, to deliver the first Leksell Gamma Knife Icon to Asia. [More]
Surgical resection, chemo and radiation therapy combination may help treat metastatic lung cancer

Surgical resection, chemo and radiation therapy combination may help treat metastatic lung cancer

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery. [More]
FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan. [More]
Elekta's Leksell Gamma Knife Icon precision radiosurgery system CE marked

Elekta's Leksell Gamma Knife Icon precision radiosurgery system CE marked

Elekta has CE marked its Leksell Gamma Knife Icon precision radiosurgery system, making this latest generation Leksell Gamma Knife platform available in the European market. [More]
Massey researchers aim to develop models that can predict complications from stem cell transplantation

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. [More]
Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc, which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result. [More]
EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives. [More]
New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH. [More]
Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Varian Medical Systems today announced that it has been selected to equip and service the new multi-room HollandPTC in Delft with the Varian ProBeam proton therapy system. The company will book the equipment part of the order in its fiscal 2015 third quarter. [More]
Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. [More]
Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments. [More]
DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma. [More]
Advertisement
Advertisement